(844) 274-8497



Clinical Trials


The University of Arizona Cancer Center at Dignity Health St. Joseph’s Hospital and Medical Center leads several clinic trials within our Phoenix cancer center.

Below is a list of our active trials. Select the study name for specific information about that trial. For more information about how to participate in any of the clinical trials listed below, contact the Clinical Trials Office at 855.622.6845.

 

ABDOMINAL CANCER

David Row, MD, FACS, FASCRS

PHXB-17-0120-10-15

Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction

 

 

BASAL CELL CARCINOMA

Debra Wong, MD

PHXE-17-0101-80-15

A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

 

 

BLADDER CANCER

Jue Wang, MD

PHXE-16-0204-80-15

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

 

 

BREAST CANCER

Albert Wendt, MD

PHXA-15-0013-10-15

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

 

Albert Wendt, MD

PHXE-16-0167-10-15

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

 

Albert Wendt, MD

PHXE-17-0356-80-15

MonarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, BreastCancer

 

Albert Wendt, MD

PHXA-17-0242-71-15

Aerobic Interval Exercise Preconditioning to Prevent Cardiometabolic and Neuropsychological Complications of Anthracycline Based Breast Cancer Chemotherapy

 

Lora Hebert, MD

PHXE-17-0351-10-15

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery.

 

 

HEAD AND NECK CANCER

Panayiotis Savvides, MD

PHXB-17-0072-70-15

Clinical evaluation of everolimus (a rapamycin analog) in restoring salivary gland function to patients treated with radiotherapy for head and neck cancer

 

 

KIDNEY CANCER

Jue Wang, MD

PHXE-17-0114-10-15

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

 

 

LIVER CANCER

Nitika Thawani, MD

PHXB-13RT127

Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

 

William Cance, MD PHXE-18-0008-80-15

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

 

 

OVARIAN CANCER

John Farley, MD

PHXA-15-0002-10-15

Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

 

 

PRECISION MEDICINE

Jue Wang, MD

PHXE-17-0216-10-15

EAY131: Molecular Analysis for Therapy Choice (MATCH)

 

 

PROSTATE CANCER

Jue Wang, MD

PHXE-17-0128-80-15

An Open-Label Phase 1/2A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRC253, and Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer

 

 

RARE TUMORS

Jue Wang, MD

PHXE-17-0349-10-15

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

 

 

Learn More

For more information or to participate, call the Clinical Trials Office at 855.622.6845.